BridgeMD
Tests treatment safety and results for Metabolic Syndrome
Official title Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome
ClinicalTrials.gov ID: NCT06410352
What this study is testing
What is Semaglutide, Empagliflozin?
Semaglutide, Empagliflozin is an investigational medicine, given as an once-daily injection under the skin, being studied as a potential treatment for metabolic syndrome.
Also referred to as Semaglutide (GLP-1RA), Empagliflozin (SGLT-2i).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Background. The prevalence of type 2 diabetes mellitus (T2D) in the world is constantly increasing.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 35 to 65
You may be able to join if
- written informed consent;
- T2D≥3-year with glucose lowering therapy including insulin;
- 35-55 years old;
- BMI≥27 kg/m2 for both sex, for Asian ethnicity;
- ongoing treatment with antihypertensive treatment;
You likely can't join if
- T1D;
- \ 56 years old;
- unstable cardiac disorders (New York Heart Association class IV heart failure, refractory angina, uncontrolled arrhythmias, critical valvular heart...
- glomerular filtration rate \<30 mL/min and/or dialysis within 14 days before screening; malignancy within the past 5 years;
- gestation or lactation;
- hereditary diseases;
See the full eligibility criteria
- written informed consent;
- T2D≥3-year with glucose lowering therapy including insulin;
- 35-55 years old;
- BMI≥27 kg/m2 for both sex, for Asian ethnicity;
- ongoing treatment with antihypertensive treatment;
- weight loss 15-20% at baseline and dynamic follow-up up to 24 weeks.
- T1D;
- \ 56 years old;
- unstable cardiac disorders (New York Heart Association class IV heart failure, refractory angina, uncontrolled arrhythmias, critical valvular heart disease, or severe uncontrolled hypertension);
- glomerular filtration rate \<30 mL/min and/or dialysis within 14 days before screening; malignancy within the past 5 years;
- gestation or lactation;
- hereditary diseases;
- known hypersensitivity to any of the test substances.
The study team makes the final eligibility decision.
Where it's taking place
- Astana, Astana, Kazakhstan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 35 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Astana, Astana, Kazakhstan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.